Literature DB >> 25645822

Tacrolimus and mycophenolate mofetil associations: Induction of oxidative stress or antioxidant effect?

H Ferjani1, A Achour2, H Bacha3, S Abid1.   

Abstract

Gastrointestinal risk factors after organ transplantation are prevalent, due to the chronic use of immunosuppressant. The immunosuppressive drugs such as tacrolimus/mycophenolate mofetil (TAC/MMF) association are the most commonly used therapy. TAC and MMF have been implicated in gastrotoxicity, but their direct effects, alone and combined, on intestinal cells are not completely elucidated. This study investigated the effect of TAC and MMF alone and combined on human colon carcinoma cells. Our results demonstrated that TAC and MMF individually inhibit clearly cells proliferation, enhanced free radicals, lipid peroxidation production, induced DNA lesions and reduced mitochondrial membrane potential. In this study, we also showed that the two molecules TAC and MMF combined at high concentrations amplified the cell damage. Furthermore, the TAC (5 µM) prevented cell death induced by MMF (half maximal inhibitory concentration (IC(50))). Also, MMF (50 µM) induced cytoprotection in HCT116 cells against TAC (IC(50)) toxicity. Our findings provide additional evidence that oxidative damage is the major contribution of TAC and MMF combined toxicities. In fact, MMF and TAC exert a gastroprotective effect by modulating reactive oxygen species production. These data underscore the pleiotropic effect of TAC and MMF on HCT116 cells that play a preventive and critical role on intestinal function.
© The Author(s) 2015.

Entities:  

Keywords:  Tacrolimus; combination; free radicals; genotoxicity; lipid peroxidation; mycophenolate mofetil

Mesh:

Substances:

Year:  2015        PMID: 25645822     DOI: 10.1177/0960327115569812

Source DB:  PubMed          Journal:  Hum Exp Toxicol        ISSN: 0960-3271            Impact factor:   2.903


  2 in total

1.  Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats.

Authors:  Hanen Ferjani; Amira El Arem; Aicha Bouraoui; Abedellatif Achour; Salwa Abid; Hassen Bacha; Imen Boussema-Ayed
Journal:  J Physiol Biochem       Date:  2016-01-09       Impact factor: 4.158

2.  Tacrolimus ameliorates tubulointerstitial inflammation in diabetic nephropathy via inhibiting the NFATc1/TRPC6 pathway.

Authors:  Shumin Zhang; Huafen Wang; Yifei Liu; Wenxia Yang; Jialu Liu; Yuzhang Han; Yu Liu; Fuyou Liu; Lin Sun; Li Xiao
Journal:  J Cell Mol Med       Date:  2020-08-11       Impact factor: 5.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.